

SWIXX AND OTSUKA EXPAND PARTNERSHIP WITH LUPKYNIS® AND ABILIFY®

SWIXX ANNOUNCEMENT NO. 50

January 3rd, 2023

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, announced today an extension of its existing relationship with Otsuka Pharmaceutical Europe Ltd. of Wexham, United Kingdom, to include additional portfolio and territory. In addition to commercializing Jinarc® (tolvaptan), Swixx will now also commercialize Lupkynis® (voclosporin), covering the countries of Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia. The Otsuka – Swixx partnership will also expand to the territory of Malta.

In addition, Swixx will be appointed as the exclusive representative of Otsuka for Abilify® (aripiprazole), in the countries of Bulgaria, Czech Republic, Greece, Estonia, Hungary, Latvia, Lithuania, Poland and Slovenia.

“We are very pleased to extend our partnership with Otsuka to Lupkynis (voclosporin).” commented Swixx COO, Dr. Dezso Martha. “In addition, we are pleased increase our geographic coverage to Malta and to expand our successful collaboration with an established psychiatric brand Abilify® (aripiprazole). We see the addition of Abilify as an important step for Swixx, as it extends our reach in the CNS therapeutic area, which already includes treatments for epilepsy/bipolar disorder and multiple sclerosis.”

About Lupkynis® (voclosporin) and Abilify® (aripiprazole)

Lupkynis® (voclosporin) has been approved by the European Medicines Agency (EMA) in September 2022 and is indicated for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis in combination with mycophenolate mofetil¹.

Abilify® (aripiprazole) is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older; the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment; the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older³. Abilify (aripiprazole) solution for injection is indicated for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder, when oral therapy is not appropriate².

For further information, please refer to

<https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis>
<https://www.ema.europa.eu/en/medicines/human/EPAR/abilify>

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries plus Moldova and Uzbekistan. With over 1100 employees and sales likely to exceed 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE and Russia. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG

vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086

References:

¹Lupkynis EPAR, available at https://www.ema.europa.eu/en/documents/overview/lupkynis-epar-medicine-overview_en.pdf, last accessed: December 2022.

²Abilify Summary of Product Characteristics, available at: https://www.ema.europa.eu/en/documents/product-information/abilify-epar-product-information_en.pdf, last accessed: December 2022.